Eligible patients had metastatic lesions measuring 5–20 mm, had no neurologic symptoms, did not require corticosteroids, and for the NSCLC cohort were required to have positive tumor PD-L1 expression. The gene discussed is CD274; the disease is non-small cell lung carcinoma.